Cytogen to ship ProstaScint to first 65 certified sites in early 1997 following Oct. 28 approval.
This article was originally published in The Gray Sheet
Executive Summary
CYTOGEN's PROSTASCINT INITIAL AVAILABILITY WILL BE LIMITED TO 65 SITES certified by the American College of Nuclear Physicians, Cytogen President and CEO Thomas McKearn, MD, PhD, said during an Oct. 29 analyst teleconference following approval of the prostate cancer diagnostic imaging agent on Oct. 28. "Using our `Partners in Excellence' program, which involves training people and certifying them in the proper interpretation of the test results...we will be in the marketplace with about 65 of these sites by the time we introduce the product," McKearn said. Cytogen plans to launch the product in early 1997.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.